Company profile
Vicore Pharma Holding AB
NASDAQ:VCREBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Buloxibutid | phase3 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06588686 | phase2 | active_not_recruiting | 2024-12-09 | 2027-05-01 | Vicore Pharma AB | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
| NCT05831644 | phase1 | completed | 2023-03-31 | 2023-06-16 | Vicore Pharma AB | A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes |
| NCT05830799 | phase1 | completed | 2023-03-29 | 2023-05-11 | Vicore Pharma AB | A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers |
| NCT04880642 | phase3 | completed | 2021-09-16 | 2022-04-25 | Vicore Pharma AB | A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects |
| NCT04388176 | phase2 | completed | 2020-01-03 | 2020-12-14 | Vicore Pharma AB | Cold Challenge With C21 in RP |
FDA applications (0)
No records yet.